Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.76 |
| ▸ | ABCC2 | Q92887 | 3/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.76 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.76 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.76 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.76 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30478470 | 1.00 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL30478462 | 1.00 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL30248308 | 1.00 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL29477253 | 1.00 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL30248384 | 1.00 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL30478471 | 1.00 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL29477244 | 0.99 | ABCB11 (0.77) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL29477247 | 0.98 | ABCB11 (0.77) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL30478467 | 0.96 | ABCB11 (0.76) | ABCB11MAPTABCC4ABCC2CHRM1 | |
| SCHEMBL30115796 | 0.95 | ABCB11 (0.74) | ABCB11MAPTABCC4ABCC2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | JAZZ PHARMACEUTICALS THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12447163-B2 | Liposomal formulations of Bcl inhibitors | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240350411-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | Jazz Pharmaceuticals Therapeutics, Inc. | 2024-10-24 | — | — | US | disclosed |
| EP-4370099-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | Celator Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4370098-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | Celator Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117897140-A | Method for preparing liposome preparation | 塞拉特药物股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117897139-A | Liposome formulations of BCL inhibitors | 塞拉特药物股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-116515996-A | Kit for screening colorectal cancer and adenoma in progressive stage | 上海伯豪生物技术有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-11600045-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230059528-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2023288103-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288100-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220366648-A1 | Collaborative Light Show Authoring for Tessellated Geometries | CONTRAVENTUM, LLC (US) | 2022-11-17 | — | — | US | disclosed |
| US-11282276-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | BCL2, BCL3, BCL2L1 | ABCB11 445/4885MAPT 3854/4885ABCC4 692/4885 |
| US-20240350411-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | LIPA, PHOSPHO1, LPXN | ABCB11 757/4885MAPT 3744/4885ABCC4 3203/4885 |
| US-12447163-B2 | Liposomal formulations of Bcl inhibitors | BCL6, BCL3, BCL2L1 | ABCB11 2776/4885MAPT 3943/4885ABCC4 2255/4885 |
| US-20230059528-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | BCL6, BCL3, BCL2L1 | ABCB11 2776/4885MAPT 3943/4885ABCC4 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.